# US 2025/0025456 A1 · Pharmaceutical compositions of cabozantinib

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0025456 A1
- Document ID: US20250025456A1
- Status: Published application
- Kind: A1
- Application number: 18/901,359
- Filed: 2024-09-30
- Published: 2025-01-23
- Earliest claimed: 2021-02-19
- Assignees: Slayback Pharma LLC
- Applicants: Slayback Pharma LLC
- Inventors: Sushant Omprakash DUBE; Suprit Dilip SAOJI; Pankaj Kisan CHATKI; Sumitra Ashokkumar PILLAI; Girish G. KORE
- Web page: https://patentgrep.com/patent/US20250025456A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 9/10: Dispersions; Emulsions
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.

## Claims

### Claim 1

A pharmaceutical composition suitable for oral administration comprising a therapeutically effective amount of cabozantinib in the form of an amorphous solid dispersion and at least one pharmaceutically acceptable excipient, wherein said amorphous solid dispersion consists of
a) cabozantinib or a pharmaceutically acceptable salt thereof;
b) a pharmaceutically acceptable carrier;
c) a pore-forming agent selected from group consisting of hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), lactose, mannitol, and mixtures thereof; and
d) a plasticizer.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable salt of cabozantinib is cabozantinib (S)-malate.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises from about 2.5 mg to about 140 mg of the cabozantinib.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable carrier comprises hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the plasticizer is polyethylene glycol (PEG).

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein a weight percentage of the plasticizer ranges from 4 to 8% w/w of the total composition.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein a weight percentage of the plasticizer ranges from 4 to 14% w/w of the amorphous solid dispersion.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the at least one pharmaceutically acceptable carrier in the amorphous solid dispersion is selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), carboxymethyl cellulose (CMC), polyvinyl pyrrolidine (PVP), and mixtures thereof.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the amorphous solid dispersion of cabozantinib has a weight ratio of the cabozantinib to the at least one pharmaceutically acceptable carrier from about 1:1 to about 1:6.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the amorphous solid dispersion of cabozantinib has a weight ratio of the cabozantinib to the at least one pharmaceutically acceptable carrier from about 1:1 to about 1:5.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the amorphous solid dispersion of cabozantinib has a weight ratio of the cabozantinib to the at least one pharmaceutically acceptable carrier from about 1:1 to about 1:4.

### Claim 12 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the at least one pharmaceutical acceptable excipient is selected from the group consisting of diluents, binders, disintegrants, lubricants, glidants, surfactants, plasticizers, pore-forming agents, stabilizing agents, antioxidants, coating agents and combinations thereof.

### Claim 13 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a tablet or a capsule.

### Claim 14 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said composition provides about 30% enhanced C max and about 30% enhanced AUC0-72 hr, compared to a drug product corresponding to National Drug Code Number 42388-023 and NDA 208692 having the same therapeutically effective amount of cabozantinib, following oral administration in human subjects under fasting condition.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the amorphous solid dispersion of cabozantinib may be prepared by hot-melt extrusion, spray-drying or co-precipitation.
